PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2096351
PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2096351
The global mass spectrometry market is projected to reach USD 10,783.3 million by 2031 from USD 7,074.0 million in 2026, at a CAGR of 8.8% from 2026 to 2031.
| Scope of the Report | |
|---|---|
| Years Considered for the Study | 2026-2031 |
| Base Year | 2025 |
| Forecast Period | 2026-2031 |
| Units Considered | Value (USD billion) |
| Segments | Product, Inlet Type, Application, End User, and Region |
| Regions covered | North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa |
The global mass spectrometry market is experiencing strong growth driven by the rapid expansion of precision medicine, biologics development, multi-omics research, and regulatory-driven bioanalytical testing across pharmaceutical, biotechnology, clinical diagnostics, food safety, and environmental sectors. One of the latest trends accelerating market growth is the increasing adoption of high-resolution LC-MS/MS and hybrid mass spectrometry platforms integrated with AI-enabled analytics, automation, cloud-connected laboratory workflows, and robotic sample preparation to improve throughput, reproducibility, and operational efficiency.

Pharmaceutical and biopharmaceutical companies are heavily investing in advanced mass spectrometry systems for biomarker discovery, antibody-drug conjugate (ADC) characterization, cell and gene therapy development, and FDA-compliant pharmacokinetic analysis, while hospitals and diagnostic laboratories are increasingly deploying benchtop clinical LC-MS/MS systems for endocrinology, toxicology, and precision oncology testing. Additionally, the rapid growth of outsourced bioanalytical services through CROs, increasing PFAS and environmental contaminant testing, and the transition toward digitally integrated and standardized analytical ecosystems are further strengthening global demand for next-generation hybrid and high-throughput mass spectrometry platforms.
The instruments segment accounted for the largest share of the mass spectrometry market.
By product, the mass spectrometry market is segmented into instruments, software, and services. During the forecast period, the instruments segment is projected to hold the largest share of the mass spectrometry market owing to increasing investments in advanced analytical technologies across pharmaceutical, biotechnology, clinical research, and multi-omics applications. The growing demand for high-performance mass spectrometry instruments is being driven by the rising complexity of drug development workflows involving biologics, antibody-drug conjugates (ADCs), cell and gene therapies, and precision medicine initiatives. Pharmaceutical and biopharmaceutical companies are increasingly investing in next-generation mass spectrometry platforms with improved sensitivity, high-resolution analysis, automation, and AI-enabled workflow capabilities to enhance bioanalytical efficiency, accelerate research timelines, and ensure regulatory compliance. Furthermore, developed regions such as North America and Europe are witnessing faster instrument replacement and upgrade cycles due to continuous technological innovation and the increasing adoption of high-throughput analytical systems across research laboratories, hospitals, and clinical institutions.
"The LC-MS segment accounted for the largest share of the mass spectrometry market."
By inlet type, the mass spectrometry market is segmented into GC-MS, LC-MS, ICP-MS, and other inlet types. During the forecast period, the LC-MS segment is expected to dominate the global mass spectrometry market owing to its widespread adoption across pharmaceutical, biotechnology, clinical diagnostics, food safety, and environmental testing applications. LC-MS is one of the most extensively utilized analytical techniques for the identification and quantification of complex biological and chemical compounds with high sensitivity and accuracy. The segment is witnessing significant growth due to increasing regulatory acceptance, expanding biologics and precision medicine research, and rising demand for advanced bioanalytical testing workflows. One of the major market trends driving LC-MS adoption is the implementation of ICH M10 bioanalytical method validation guidelines by the U.S. Food and Drug Administration and other international regulatory agencies, which recognize LC-MS/MS as the preferred technology for pharmacokinetic analysis, biomarker quantification, and regulated drug testing. This regulatory shift is encouraging pharmaceutical companies and contract research organizations to increase investments in next-generation LC-MS/MS platforms to support clinical development, regulatory compliance, and high-throughput drug analysis applications.
"The pharma/biopharma manufacturing application segment accounted for the largest share of the mass spectrometry market."
The pharmaceutical and biopharmaceutical sectors are emerging as major application areas and key news trends in the mass spectrometry market due to the growing demand for advanced analytical technologies in drug discovery, biologics characterization, biomarker identification, and GMP-compliant quality control. Pharmaceutical companies are increasingly adopting LC-MS/MS and high-resolution mass spectrometry systems to support complex biologics, antibody-drug conjugates, peptides, cell and gene therapies, and biosimilar development, where traditional analytical methods are often insufficient. The rising focus on precision medicine, regulatory compliance, impurity profiling, and real-time process monitoring is further accelerating the adoption of advanced mass spectrometry platforms across pharmaceutical R&D and manufacturing operations.
In addition, the rapid expansion of omics research, proteomics, metabolomics, and personalized medicine is driving continuous innovation and product launches in the mass spectrometry industry. Leading companies are introducing automated, high-throughput, and AI-enabled mass spectrometry solutions to support translational research and biopharma workflows. The increasing outsourcing of bioanalytical testing to CROs and CDMOs, along with growing investments in biologics and advanced therapies, is further strengthening the role of mass spectrometry in pharmaceutical and biotechnology applications. These trends are positioning pharma and biopharma as the fastest-growing and highest-revenue-generating application segments within the global mass spectrometry market.
By end-user, the pharmaceutical companies segment is projected to account for the largest market share during the forecast period.
By end user, the mass spectrometry market is segmented into pharmaceutical companies, biotechnology companies, research laboratories & academic institutes, environmental testing laboratories, food & beverage industry, hospital clinical & forensic laboratories, petrochemical industry, and other end users. During the forecast period, the pharmaceutical companies segment is expected to register the fastest growth owing to the increasing adoption of advanced analytical technologies in biologics development, precision therapeutics, and multi-omics-based drug discovery workflows. One of the major trends driving growth in this segment is the rising deployment of advanced hybrid mass spectrometry platforms such as Orbitrap, Q-TOF, Triple Quadrupole Linear Ion Trap, and FT-MS systems for complex biologic characterization, antibody-drug conjugate (ADC) analysis, host-cell protein monitoring, and real-time process analytical technology (PAT) applications. Pharmaceutical and biopharmaceutical manufacturers are increasingly integrating high-resolution hybrid MS systems into manufacturing, quality control, and bioanalytical environments to support continuous bioprocessing, impurity profiling, glycosylation studies, and ultra-trace contaminant detection. This trend is particularly prominent in monoclonal antibody, mRNA, and cell therapy manufacturing facilities, where next-generation therapeutics require highly sensitive and high-resolution analytical capabilities beyond conventional testing technologies.
"Asia Pacific is projected to show the highest growth rate in the mass spectrometry market."
The mass spectrometry market spans five primary regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia-Pacific mass spectrometry market is witnessing rapid transformation driven by the expansion of biologics manufacturing, multi-omics research, precision medicine programs, and large-scale pharmaceutical outsourcing across China, India, Japan, South Korea, and Southeast Asia. One of the latest trends is the increasing deployment of high-resolution hybrid LC-MS/MS, Orbitrap, and Q-TOF systems in CROs, CDMOs, and biopharmaceutical manufacturing facilities for advanced biologic characterization, impurity profiling, glycan analysis, and cell & gene therapy workflows. Governments across the region are heavily investing in genomics, proteomics, metabolomics, and translational medicine initiatives, accelerating the adoption of AI-enabled and cloud-connected mass spectrometry platforms in both research and clinical diagnostics environments. Another major trend reshaping the region is the rapid digitalization of analytical laboratories through robotic sample preparation, laboratory information system (LIS) integration, and automated bioanalytical workflows to support high-throughput drug development and regulatory compliance. Additionally, APAC is emerging as a global pharmaceutical and bioanalytical outsourcing hub, creating strong recurring demand for advanced LC-MS infrastructure among CROs and contract testing laboratories.
The major players in the mass spectrometry market include Thermo Fisher Scientific (US), Agilent Technologies (US), Sciex (US), Waters Corporation (US), Bruker (US), Shimadzu Corporation (Japan), and PerkinElmer Inc. (US), among others.
Research Coverage
The research report examines the mass spectrometry market by product, inlet type, application, end users, and region. This research covers factors that are driving market expansion, analyzes prospects and parameters faced by industries in the present time, and provides specifics on the competitive landscape, considering market leaders and small and medium enterprises. This research also estimates the revenue of different market segments by considering five regions and micro-market analysis.
Reasons to Buy the Report
The report will provide market leaders and new entrants with valuable information regarding the revenue estimates for the overall mass spectrometry market and its subsegments. It will help stakeholders understand the competitive landscape, allowing them to position their businesses more effectively and develop appropriate go-to-market strategies. Additionally, the report offers insights into the market dynamics, including key drivers, restraints, challenges, and opportunities.
16.3 GROWTH FORECASTING MODEL